Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0242379 (lung cancer)
 71,905 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A case of 70-year old male manifesting a simultaneous adenocarcinoma, malignant lymphoma and silicotuberculosis in the same lung has been reported. The patient, who had worked as a miner for 24 years and had been treated for silicosis 11 years previously, was found to have a new, abnormal shadow during a routine chest X-ray. Later, sputum cytology revealed the adenocarcinoma. He was treated with chemotherapy, but died 24 months later, his death attributed to lung cancer, complicated with respiratory insufficiency and weakness. An autopsy confirmed the presence of an adenocarcinoma and silicotuberculosis, and a histological examination revealed the coexistence of malignant lymphoma in the same lung.
 ...
PMID:[An autopsy case revealing the simultaneous coexistence of adenocarcinoma, malignant lymphoma and silicotuberculosis in the same lung]. 340 54

A review of epidemiological studies on the health effects of exposure to phenoxy herbicides suggests that exposure may be associated with an increased incidence of cancer and unfavorable outcomes of pregnancy. Studies on cancer have found increased risks of 5.3, 6.8 and 3.96 for soft-tissue sarcoma, 7.7 and 6.0 for stomach cancer, 2.05 for lung cancer, 4.8 for lymphoma, 2.3 for all cancers combined, and 5.2 for liver cancer after exposure to 2,4,5-T or dioxin contaminants. Several studies have suggested a possible increase in birth defects after paternal exposure. An increased risk of hydatidiform mole is suggested by Vietnamese studies on the effects of maternal exposure.
 ...
PMID:Health effects of phenoxy herbicides. A review. 352 76

Epidemiologic studies have suggested an increased risk of leukemia and lymphoma among workers exposed to styrene. In a further exploration of this possible hazard, an analysis was conducted of the mortality among 7,949 men and women employed during 1947-1984 in eight British companies manufacturing glass-reinforced plastics. The subjects were identified from company files and traced to the end of 1984 through National Health Service and National Insurance records. The overall mortality in the cohort was less than in the national population (693 deaths observed, 830.1 expected) as was mortality from cancer (181 deaths observed, 223.7 expected). In particular, there was a deficit of deaths from lymphoid and hemopoietic cancer (6 observed, 14.9 expected). The small excess of lung cancer (89 deaths observed, 80.1 expected) was not statistically significant and can probably be attributed to chance. Among 3,494 hand laminators (the job with the highest exposure to styrene) there was one death from lymphoma and none from leukemia. The findings do not exclude the possibility that styrene is a human carcinogen, but give no support to the hypothesis that it causes leukemia and lymphoma.
 ...
PMID:Mortality of workers exposed to styrene in the manufacture of glass-reinforced plastics. 360 70

The activity, content and true specific activity of superoxide dismutase (SOD) were determined for human erythrocytes of 105 normal healthy subjects. At the same time the activities of erythrocyte SOD are also determined in patients with lung cancer, lymphoma, leukemia and thyroidal dysfunctions. The mean SOD activity of healthy subjects assayed by the method of inhibition of xanthine autoxidation was 11.0 X 10(3) units/g of hemoglobin (Hb). The mean SOD content of healthy subjects assayed by an immunodiffusion method was 456 micrograms/g of Hb. Both the activity and the content of SOD showed normal distributions, while no significant variations in regard to sex and age were detected. A high positive correlation between the activity and the content of SOD was observed in normal healthy subjects (r = 0.77, p less than 0.001). True specific activity was calculated from the levels of activity and content of SOD. The mean true specific activity of SOD in human erythrocytes was 23.7 units/micrograms of SOD. There was no significant difference in true specific activity among age groups. The activity of erythrocyte SOD was determined in 38 patients with lung cancer (n = 15), malignant lymphoma (n = 11) and acute myeloid leukemia (n = 12). Patients with malignant lymphoma and acute myeloid leukemia showed a significant decrease in enzyme activity (p less than 0.01) while the patients with lung cancer (9 squamous cell carcinomas and 6 small cell carcinomas) showed a normal value of SOD activity. Furthermore, patients with malignant lymphoma and acute myeloid leukemia who were in remission and were not being treated with anticancer drugs also showed a significant decrease in SOD activity. These observations therefore indicate that a low level of erythrocyte SOD activity is related to cancer and that degree of the activities varies with the type of cancer. A total of 18 determinations of erythrocyte SOD activity were made on 16 patients with thyroidal dysfunction. Patients with hyperthyroidism showed a significant increase in SOD activity (p less than 0.01), while patients with hypothyroidism showed the same SOD activity as those of healthy subjects. A significantly high positive correlation was found between erythrocyte SOD activity and the level of thyroxine in serum (r = 0.60, p less than 0.01). The author suggests therefore that erythrocyte SOD activity has a close relationship to the state of the thyroid hormones.
 ...
PMID:Superoxide dismutase level in human erythrocytes and its clinical application to the patients with cancers and thyroidal dysfunctions. 361 27

Two hundred and eighty-six patients presenting with metastatic adenocarcinoma or undifferentiated carcinoma whose primary site was not identified by clinical history, physical examination and chest radiograph have been studied. Median survival from presentation was 22 weeks. Factors independently predicting improved survival were lymph node presentations, good performance status and body weight loss of less than 10 per cent. In 88 (31 per cent) patients the primary tumour site was subsequently identified, in 58 (20 per cent) during life. Lung cancer was the most frequently identified primary tumour, and in only 32 (11 per cent) of the patients was a 'treatable' primary tumour (i.e. germ cell, breast, ovarian, prostate, thyroid cancer or lymphoma) identified. Among the treatable primary tumours were those in eight out of 16 female patients presenting with axillary metastases who were subsequently shown to have primary breast cancer and four of 13 females presenting with ascites who were found to have primary ovarian cancer. Prostatic cancer was confirmed in five out of 13 men with raised serum acid phosphatase. Of 22 patients with elevated serum alphafoetoprotein (AFP) or beta-human chorionic gonadotrophin levels (beta HCG) 18 had some features of the 'atypical teratoma syndrome'. Of the total of 32 patients with treatable tumour types, 29 (90 per cent) were identified during life. Median survival for patients with treatable tumour types identified during life was 104 weeks, compared with 22 weeks for the group as a whole. Retrospective immunocytochemical staining of the original biopsy showed that prostatic specific antigen and antibodies to beta HCG and AFP were diagnostically useful, but a series of organ site non-specific markers of histogenesis or cellular differentiation (carcinoembryonic antigen, secretory component for IgA, peanut lectin binding, epithelial membrane antigen and keratin) showed no significant correlations with identified primary sites, responsiveness to empirical chemotherapy or survival. Metastatic undifferentiated carcinoma or adenocarcinoma from an unknown primary site represents 6.5 per cent of all referrals to the medical oncology unit, Royal Prince Alfred Hospital, Sydney. We offer guidelines for the rapid identification of the limited number of primary sites for which effective and specific forms of systemic treatment are available.
 ...
PMID:Metastatic adeno or undifferentiated carcinoma from an unknown primary site--natural history and guidelines for identification of treatable subsets. 365 56

During a follow-up of 665 patients with carcinoma of the breast age 40 years or older, 46 developed a second primary carcinoma of the opposite breast and 30 developed a nonmammary malignancy (median FU = 6 yrs). Comparing our number of observed cases with the number of expected cases (calculated from the female age-specific incidence rate of the data of the Surveillance, Epidemiology and End Results (SEER) and from the actual cumulative person-years of follow-up), our patients with breast cancer did not have higher probability of developing additional nonmammary malignancy, but did have over five times the chance of developing a second breast cancer as other females to have any such cancer. Comparing the distribution of specific sites of our nonmammary second cancer with that reported by the SEER's study, the proportions of patients with colorectal, lung cancer, and lymphoma were similar. But we did see relatively more carcinomas of the uterine cervix, ovary, vulva, sarcoma, and stomach/duodenum, and fewer carcinoma of the endometrium. These differences could be explained by our small series, patient characteristics, and selected referral pattern.
 ...
PMID:Additional malignant neoplasms in patients with breast carcinoma. 372 72

Antineoplaston AS2-5 is one of the degradation products of Antineoplaston A10. The chemical structure of Antineoplaston AS2-5 corresponds to phenylacetylglutamine. Toxicology studies of Antineoplaston AS2-5 injections involved 13 patients diagnosed with 15 types of neoplastic disease, including: lung cancer, 3 cases; breast, 3 cases; colon, 2 cases; and single cases of cancer of the larynx, prostate, stomach, pancreas, malignant fibrohistiocytoma, embryonal teratoma and lymphocytic lymphoma. Antineoplaston AS2-5 was injected i.v. daily through subclavian vein catheter in divided doses. The treatment was administered from 41 to 436 days. The highest dosage given was 167.6 mg/kg/24 h. The treatment was associated with only very mild side-effects, including febrile reaction in two patients and swelling of small joints in one patient. Two patients had beneficial side-effects, including increase of platelet count and increase of concentration of plasma globulin. The treatment resulted in two complete remissions, one mixed response, four cases of stabilization and six cases of increasing disease. Complete remission was achieved in squamous cell carcinoma of the larynx, stage II, and large cell undifferentiated carcinoma of the lung with lymph nodes and liver metastases. One patient had mixed response during the treatment of carcinoma of the breast with metastases to the lymph nodes, liver and skin and obtained complete remission of liver metastases but increasing disease of skin metastases. Eight patients discontinued the treatment and three patients died during the trials. The patient diagnosed with lung cancer who obtained complete remission continues to be free from the disease over 5 years after the beginning of the treatment.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Toxicology studies on antineoplaston AS2-5 injections in cancer patients. 374 77

Antineoplaston AS2-1 is a mixture of two products of hydrolysis of Antineoplaston A10 and consists of sodium salts of phenylacetylglutamine and phenylacetic acid in the ratio of 1:4. Antineoplaston AS2-1 injections were administered to 20 patients diagnosed with 21 types of neoplastic diseases. The patients' diagnoses included: lung cancer, stage III, 4 cases; colorectal, stage IV, 3; breast, stage IV, 2; breast in remission, 1; glioblastoma, 3; head and neck, stage IV, 3; uterine cervix, stage IA, 1; chronic myelocytic leukaemia, 2; lymphocytic lymphoma, stage IV, 1; and leiomyosarcoma of the uterus, stage IVB, 1. Antineoplaston AS2-1 was administered every 6 h i.v. through subclavian vein catheter. The treatment was administered from 38 to 872 days. The highest dosage taken was 160 mg/kg/24 h. The treatment was associated with minimal side-effects, including slight nausea and vomiting in one patient, mild allergic reaction in the form of maculopapular rash in another patient and moderate elevation of blood pressure in an additional patient. One patient developed febrile reaction and three patients had mild electrolyte imbalance. Only one patient showed slight decrease of WBC. Desirable side-effects included improved healing of chronic atrophic ulceration. The response to the treatment included 6 complete remissions, 2 partial remissions, 7 cases of stabilization and 6 cases of increasing disease. Three patients are alive, well and free from cancer 5 years after the beginning of the study. The hypothetical mechanism of action of Antineoplaston AS2-1 as an anticancer agent is described.
 ...
PMID:Toxicology studies on antineoplaston AS2-1 injections in cancer patients. 374 78

True annular malignancies of the small bowel with mucosal destruction and shelflike margins are generally thought to be caused by primary adenocarcinoma. At our institution, 18 annular malignancies were diagnosed radiographically in the small bowel by enteroclysis (16 cases) and conventional small bowel follow-through studies (2 cases) between 1977 and 1984. However, pathologic data revealed only 4 primary adenocarcinomas with 10 metastatic lesions (6 colon cancers, 2 malignant melanomas, 1 lung cancer, and 1 cervical cancer), 2 leiomyosarcomas, 1 non-Hodgkin's lymphoma, and 1 malignant carcinoid tumor. While these lesions may be indistinguishable radiographically, annular carcinomas tended to be short, relatively nonobstructing lesions; annular metastases (except those from malignant melanoma) tended to be highly obstructing lesions with significant narrowing and/or angulation of the bowel. Leiomyosarcomas, lymphoma, and metastases from malignant melanoma tended to be longer lesions with extensive ulceration, wider channels, and little or no evidence of obstruction. Nevertheless, surgical resection or biopsy of the lesion is ultimately required for a definitive diagnosis.
 ...
PMID:Annular malignancies of the small bowel. 379 59

One hundred and fifty-nine patients with symptoms of superior vena caval obstruction who presented to two major hospitals over a 10-year period, from 1970 to 1979, were reviewed. Lung cancer was the most common histological diagnosis. The most common symptoms were dyspnoea and a feeling of fullness in the head. The most common physical findings were dilatation of the neck or chest wall veins, or oedema of the face and arms. Superior mediastinal widening was the most common radiological abnormality. No significant morbidity was associated with any diagnostic procedure. Only patients with lymphoma had a significantly longer survival period, both from the diagnosis of the disease, and from the onset of the symptoms of superior vena caval obstruction. There is no evidence that superior vena caval obstruction is an absolute medical emergency. Appropriate diagnostic steps should be undertaken to establish the histological diagnosis. The prognosis for some tumour types may be improved by combined modality therapy (chemotherapy plus radiotherapy).
 ...
PMID:Superior vena caval obstruction: a 10-year experience. 379 66


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>